Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
Recombinant protein drugs are intimately associated with the impressive
success story of the Biotech Industry during the past thirty years, some
of them belonging to the most successful pharmaceutical products. More
than thirty different proteins are available for a variety of clinical
applications, over 300 proteins are presently being evaluated in
In this new volume of the MDT series, historical, technical and clinical
aspects of recombinant protein drug discovery and development are
presented, covering past, present and future highlights. Leading
scientists and co-founders of early Biotech companies describe technical
breakthroughs and the fascinating story of pioneering discoveries, as
well as the long way of translating them into products and business.
Therefore, this book represents an exciting documentation of the
beginning of a new era in the pharmaceutical industry. In addition,
scientists from basic research, clinic and industry actively involved in
new developments discuss...
Content Level »Professional/practitioner
Keywords »clinic - clinical trial - development - drug - drug discovery - drugs - future - gene therapy - hepatitis - interferon - oncology - pharmaceutical - protein - protein engineering - research
Pioneers and business.- Recombinant interferon — the 20th anniversary.- Combining science and business: from recombinant DNA to vaccines against hepatitis B virus.- First generation proteins.- Clotting factors VIII and IX.- Colony-stimulating factors: altering the practice of oncology.- Tissue-type plasminogen activator: helping patients with acute myocardial infarction.- Proteins with new functions: protein engineering.- Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy.- Further improvement of protein drugs.- Improving protein therapeutics: the evolution of the modern pharmacopoeia.- Principles of gene transfer and foreign protein expression for human gene therapy.- Short biographies.- List of approved “recombinant protein drugs”.